Dr. Rule on Potential for CAR T-Cell Therapy in MCL

Video

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma (MCL).

Data on using CAR T-cell therapy to treat patients with MCL will be presented at the 2019 ASH Annual Meeting. Rule is hoping CAR T-cell therapy will be a contributing treatment and believes it will work best post-BTK inhibitor.

CAR T-cell therapy may even have the potential to replace allogeneic stem cell transplant, according to Rule. This would be a positive advance because many physicians do not like the toxicity associated with allogeneic stem cell transplant, particularly graft-versus-host disease. However, long-term data are necessary before CAR T-cell therapy is used in place of allogeneic stem cell transplant, concludes Rule.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.